{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:51Z","timestamp":1792007751861,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jhep.2023.07.014","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:17:34Z","timestamp":1690568254000},"page":"1110-1120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"79","author":[{"given":"Arun J.","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Y.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitfield","family":"Knapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-224X","authenticated-orcid":false,"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-3652","authenticated-orcid":false,"given":"Philip N.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Boursier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Michelle","family":"Berrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Shiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7946-3663","authenticated-orcid":false,"given":"Thomas","family":"Capozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jhep.2023.07.014_bib1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-med-051215-031109","article-title":"Nonalcoholic steatohepatitis","volume":"68","author":"Suzuki","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jhep.2023.07.014_bib5","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.014_bib7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.014_bib10","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2023.07.014_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.014_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818811508","article-title":"Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis","volume":"11","author":"Sayiner","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2023.07.014_bib14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib16","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.07.014_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2023.07.014_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib19","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43440-019-00020-1","article-title":"New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis","volume":"72","author":"Pydyn","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jhep.2023.07.014_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib22","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.07.014_bib23","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.3748\/wjg.v19.i42.7341","article-title":"Physiological and molecular biochemical mechanisms of bile formation","volume":"19","author":"Reshetnyak","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.07.014_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.07.014_bib25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jhep.2023.07.014_bib26","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.07.014_bib28","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2023.07.014_bib29","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.07.014_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.07.014_bib31","series-title":"Drug development for nonalcoholic steatohepatitis (NASH) with fibrosis: a regulatory perspective [presentation]. Regulatory Perspectives for Development of Drugs for Treatment of NASH webinar","first-page":"2021","author":"Matsubayashi","year":"2021"},{"key":"10.1016\/j.jhep.2023.07.014_bib32","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the division of hepatology and\u00a0nutrition\u00a0at the food and drug administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.014_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2023.07.014_bib36","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.014_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5604\/16652681.1231562","article-title":"Perspectives on NASH histology: cellular ballooning","volume":"16","author":"Caldwell","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib38","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","article-title":"Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD","volume":"76","author":"Brunt","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.07.014_bib39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.07.014_bib40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.014_bib41","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2023.07.014_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","article-title":"FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2","volume":"615","author":"Brevini","year":"2023","journal-title":"Nature"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823049930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823049930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:49:34Z","timestamp":1759175374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823049930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0168827823049930"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.07.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}